Invictus (TSXV:GENE, OTCQX: IVITF; FRA: 8IS2) the Company is pleased to announce the appointment of Trevor Dixon as a Director and Chief Operating Officer of the Company effective immediately.  Mr. Dixon is the founder, President and Chief Executive Officer of the Company’s wholly owned subsidiary Acreage Pharms Ltd. (“Acreage Pharms”).

“Mr. Dixon brings 35 years of successful business experience to the leadership team of Invictus,” said George E. Kveton, CEO of Invictus. “Trevor will continue to hold his current positions within Acreage Pharms,” continued Mr. Kveton.


Mr. Dixon stated that, “moving forward, it is my intention to create synergy with all of the Invictus companies and to continue to grow and further increase the Company’s production and sales.”

Mr. Dixon advised that “Phase I and II at the Acreage Pharms facilities, located near Edson, Alberta, are in full production utilizing all eleven flowering rooms for growing both medical and recreational cannabis.  Acreage Pharms continues to increase its bottled cannabis oil inventory while it awaits approval of its oil sales license in accordance with Health Canada’s Cannabis Act and Cannabis Regulations.  The Company eagerly awaits Acreage Pharms entering into production in its Phase III, 90,000 square foot, state of the art facility when the anticipated license amendment is awarded by Health Canada, which is expected in the fall of this year.”

Acreage Pharms obtained a Health Canada license to produce, grow and harvest medical cannabis on March 29, 2017and received its sales license on May 18, 2018. Acreage Pharms continues to accept patients and retail orders for cannabis. Effective August 3, 2018, Health Canada amended Acreage Pharms license to include the production of cannabis oil and cannabis resin.

On Behalf of the Board,
George E. Kveton
Chief Executive Officer and Director

Investor Relations
1-844-800-6086

About Invictus

Invictus is a global cannabis company offering a selection of products under a wide range of brands. Our integrated sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores.

Acreage Pharms Ltd. has designed and is building the Phase 3, purpose-built cultivation facility, to meet all European Union Good Manufacturing Practices to facilitate international medical cannabis sales.

The Company is targeting 50 percent of its production for medical cannabis nationally and internationally. For more information visit www.invictus-md.com.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including that Acreage Pharms is anticipated to receive approval for from Health Canada to amend their license to allow for the sale of cannabis oil is a forward-looking statement and contains forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that Acreage Pharms application to Health Canada for an amendment to their license will be successful and Acreage Pharms will receive approval for from Health Canada to amend their license to allow for the sale of cannabis oil. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, that Acreage Pharms will not receive approval for from Health Canada to amend their license to allow for the sale of cannabis oil. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Related Links

http://invictus-md.com/

Click here to connect with Invictus (TSXV:GENE, OTC:IVITF) for an Investor Presentation. 

Source: www.newswire.ca

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less